SG3 Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

SG3 Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-35,000	Closed	-$4.46M	–	1173
2021 Q4	$4.46M	Buy	+35,000	New	+$4.6M	0.09%	198
2021 Q2	–	Sell	-3,000	Closed	-$493K	–	1165
2021 Q1	$493K	Buy	+3,000	New	+$494K	0.01%	779
2017 Q2	–	Sell	-20,000	Closed	-$2.9M	–	259
2017 Q1	$2.9M	Buy	+20,000	New	+$2.6M	0.53%	43

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

SG3 Management's JAZZ Position: Q1 2022 in Review

SG3 Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 3,975 shares — an estimated $506K sold.

SG3 Management first reported a position in JAZZ in Q1 2017 and held it in 5 quarters. The position peaked at $10.7M in Q1 2021. 461 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

SG3 Management reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 3,975 Jazz Pharmaceuticals shares in Q1 2022, an estimated $506K.
SG3 Management first reported a position in Jazz Pharmaceuticals in Q1 2017 and held it in 5 quarters.
SG3 Management's Jazz Pharmaceuticals position peaked at $10.7M in Q1 2021.
461 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.